Which of the following was not true of the British drugmaker AstraZeneca's Prostodin drug marketing research study demonstrated in class?
a) It showed a significant increase in patient satisfaction.
b) It indicated a higher rate of adverse reactions compared to competitors.
c) It revealed a decrease in the average treatment cost per patient.
d) It reported a decline in the efficacy of the drug over time.